A Metastatic Cervical Adenocarcinoma Patient Carrying HER2 G292R Achieved Complete Response Upon Pyrotinib Treatment
[Paper-level Aggregated] PMCID: PMC8453302
Evidence Type(s): Oncogenic
Summary: Mutation: G292R | Summary: The G292R mutation in HER2 is implicated in tumor development or progression in cervical cancer, supporting its classification as an oncogenic variant.
Gene→Variant (gene-first): ERBB2(2064):G292R
Genes: ERBB2(2064)
Variants: G292R
A Metastatic Cervical Adenocarcinoma Patient Carrying HER2 G292R Achieved Complete Response Upon Pyrotinib Treatment
[Paper-level Aggregated] PMCID: PMC8453302
Evidence Type(s): Predictive
Summary: Mutation: G292R | Summary: The G292R mutation in HER2 is associated with a positive response to pyrotinib in a metastatic cervical adenocarcinoma patient, indicating its predictive value for treatment efficacy.
Evidence Type: Predictive
Gene→Variant (gene-first): ERBB2(2064):G292R
Genes: ERBB2(2064)
Variants: G292R
Cervical cancer patients who develop distant metastasis are rarely curable with very limited treatment options. Chemotherapy is often administered but with limited efficacy. Immunotherapy and anti-angiogenesis therapy ar
[Paragraph-level] PMCID: PMC8453302 Section: ABSTRACT PassageIndex: 2
Evidence Type(s): Predictive, Oncogenic
Summary: Evidence Type: Predictive | Mutation: G292R | Summary: The G292R mutation in HER2 is associated with a positive response to pyrotinib in a metastatic cervical adenocarcinoma patient, indicating its predictive value for treatment efficacy. Evidence Type: Oncogenic | Mutation: G292R | Summary: The G292R mutation in HER2 is implicated in tumor development or progression in cervical cancer, supporting its classification as an oncogenic variant.
Gene→Variant (gene-first): 2064:G292R
Genes: 2064
Variants: G292R
A Metastatic Cervical Adenocarcinoma Patient Carrying HER2 G292R Achieved Complete Response Upon Pyrotinib Treatment
[Paper-level Aggregated] PMCID: PMC8453302
Evidence Type(s): Oncogenic, Prognostic
Justification: Oncogenic: The G292R variant in HER2 is associated with a complete response to treatment, indicating its role in driving cancer progression and treatment response in metastatic cervical adenocarcinoma. Prognostic: The mention of a progression-free survival of 25 months in a patient with the G292R variant suggests that this variant may have implications for predicting treatment outcomes in cervical cancer.
Gene→Variant (gene-first): ERBB2(2064):G292R
Genes: ERBB2(2064)
Variants: G292R
Cervical cancer patients who develop distant metastasis are rarely curable with very limited treatment options. Chemotherapy is often administered but with limited efficacy. Immunotherapy and anti-angiogenesis therapy ar
[Paragraph-level] PMCID: PMC8453302 Section: ABSTRACT PassageIndex: 2
Evidence Type(s): Predictive, Oncogenic
Justification: Predictive: The variant G292R in HER2 is associated with a complete response to pyrotinib treatment in a patient with metastatic cervical adenocarcinoma, indicating its correlation with therapy response. Oncogenic: The passage discusses the HER2 G292R variant in the context of a metastatic cervical adenocarcinoma, suggesting that it contributes to tumor development or progression.
Gene→Variant (gene-first): 2064:G292R
Genes: 2064
Variants: G292R